This multi-year cohort study will assess the real-world safety and effectiveness of first Line (1L) treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC participant subgroups defined by age, sex, race, and ethnicity. Participants will be retrospectively identified from at least two US Electronic Health Record (EHR)-based databases.
Participants and baseline variables will be captured retrospectively, but outcome measures will be prospectively ascertained.
Study Type
OBSERVATIONAL
Enrollment
1,000
No study specific interventions for this non-interventional-observational study; participants had previously been administered this treatment.
No study specific interventions for this non-interventional-observational study; participants had previously been administered this treatment.
Regeneron Research Facility
Tarrytown, New York, United States
Real-world Response Rate (rwRR)
Time frame: Approximately 3 years
Any treatment-emergent immune-mediated Adverse Event (imAE)
Time frame: Approximately 3 years
Any treatment-emergent imAE resulting in hospitalization
Time frame: Approximately 3 years
Any treatment-emergent imAE resulting in death
Time frame: Approximately 3 years
Specific treatment-emergent imAEs
Time frame: Approximately 3 years
Real-world Duration Of Response (rwDOR)
Time frame: Approximately 3 years
Real-world Progression-Free survival (rwPFS)
Time frame: Approximately 3 years
Real-world Overall Survival (rwOS)
Time frame: Approximately 3 years
imAEs
Time frame: Approximately 3 years
Infusion-Related Reaction (IRR)
Time frame: Approximately 3 years
IRR resulting in hospitalization
Time frame: Approximately 3 years
IRR resulting in death
Time frame: Approximately 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.